Good day, ladies and gentlemen and welcome to the Q4 2012 Cardica Financial Results Conference Call. My name is Claire and I will be your operator for today. At this time all participants are in listen-only mode. We will conduct a question-and-answer session towards the end of the conference call. (Operator Instructions) As a reminder this conference is being recorded for replay purposes. I would now like to turn the call over to Bob Newell, Chief Financial Officer. Please proceed, sir. Robert Newell Good afternoon, and thank you for participating in our fiscal 2012 fourth quarter and full year financial results conference call. Earlier today we issued press release setting forth our financial results, so please refer to the release for a complete detail. The conference call will include forward-looking statements, including all statements regarding the continued clinical and other developments, products features regulatory approval, and commercial launch and use of products in our planned MicroCutter product line, including our MicroCutter XCHANGE 30, XCHANGE 45, and XPRESS 30, including the timing thereof and our expectations future support for and sales of our automated anastomosis product. Any statements contained in this conference call that are not historical facts may be deemed to be forward-looking statements. The words anticipated, expect, continue, will, can, potentially, may, plan, planned, beginning, would, will, intend, look forward and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause our results to differ materially from those indicated by these forward-looking statements, including those set forth in our press release of today as well as other risk detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2012.